Pyelonephritis Market to Grow Substantially During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Allecra, Entasis, Wockhardt, Sinovent, Nabriva, VenatoRx, Spero Therapeutics, Melinta

Pyelonephritis Market to Grow Substantially During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Allecra, Entasis, Wockhardt, Sinovent, Nabriva, VenatoRx, Spero Therapeutics, Melinta
Delveinsight Business Research LLP
DelveInsight’s “Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pyelonephritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Pyelonephritis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Pyelonephritis: An Overview

According to the National Institute of Diabetes and Digestive and Kidney Diseases, Pyelonephritis (Kidney infection) is an infection of the kidney that most often occurs when a urinary tract infection spreads beyond the bladder to the ureters and kidneys.

The most common cause of the disease is bacterial infection and based on the severity it is classified into acute and chronic pyelonephritis. The main cause of acute pyelonephritis is gram-negative bacteria, the most common being Escherichia coli. Other gram-negative bacteria which cause acute pyelonephritis include Proteus, Klebsiella, and Enterobacter. Acute pyelonephritis can be further subdivided into uncomplicated and complicated pyelonephritis.

Pyelonephritis Market Key Facts

  • A population-based study of acute pyelonephritis (APN) in the United States found overall annual rates of 15–17 cases per 10,000 females and 3–4 cases per 10,000 males (Czaja, Scholes, Hooton, & Stamm, 2007).

  • Approximately 20–35% of females experience an episode of APN in their lifetime (Clementi, 2015).

  • An estimated one in 830 people in the UK experience pyelonephritis every year, and females are six times more likely to experience the infection than males.

Pyelonephritis Market

Pyelonephritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pyelonephritis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Pyelonephritis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Pyelonephritis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Pyelonephritis Epidemiology, Segmented as –

  • Total Incidence of Pyelonephritis in the 7MM (2019–2032)

  • Gender-specific Incidence of Pyelonephritis in the 7MM (2019–2032)

  • Incidence of Pyelonephritis by Causative Agents (E. coli, Enterobacteriaceae, Pseudomonas aeruginosa, and others) in the 7MM (2019–2032)

  • Treatable Cases of Pyelonephritis in the 7MM (2019–2032)

Pyelonephritis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pyelonephritis market or expected to be launched during the study period. The analysis covers the Pyelonephritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pyelonephritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Pyelonephritis Market Will Evolve and Grow by 2032 @

Pyelonephritis Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Pyelonephritis. Currently, Wockhardt is leading the therapeutics market with its Pyelonephritis drug candidates in the most advanced stage of clinical development.

Leading Players in the Pyelonephritis Therapeutics Market Include

  • Allecra Therapeutics,

  • Entasis Therapeutics

  • Melinta Therapeutics

  • Nabriva Therapeutics

  • Sinovent

  • Spero Therapeutics

  • VenatoRx Pharmaceuticals

  • Wockhardt

And Many Others

Pyelonephritis Emerging and Marketed Drugs Covered in the Report Include:

  • Cefepime-Enmetazobactam/AAI101: Allecra Therapeutics

  • ETX2514SUL: Entasis Therapeutics

  • Pyelonephritis. Contepo: Nabriva Therapeutics

  • Tebipenem HBr (SPR994): Spero Therapeutics

  • WCK-5222: Wockhardt

  • XNW 4107: Sinovent

  • Cefepime/taniborbactam: VenatoRx Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Pyelonephritis Competitive Intelligence Analysis

4. Pyelonephritis Market Overview at a Glance

5. Pyelonephritis Disease Background and Overview

6. Pyelonephritis Patient Journey

7. Pyelonephritis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Pyelonephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Pyelonephritis Unmet Needs

10. Key Endpoints of Pyelonephritis Treatment

11. Pyelonephritis Marketed Products

12. Pyelonephritis Emerging Drugs and Latest Therapeutic Advances

13. Pyelonephritis Seven Major Market Analysis

14. Attribute Analysis

15. Pyelonephritis Market Outlook (In US, EU5, and Japan)

16. Pyelonephritis Access and Reimbursement Overview

17. KOL Views on the Pyelonephritis Market

18. Pyelonephritis Market Drivers

19. Pyelonephritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Dental Lasers Market

“Dental Lasers Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Dental Lasers market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development in the Dental Lasers Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States